GATIS score for predicting the prognosis of rectal neuroendocrine neoplasms: A Chinese multicenter study of 12-year experience

Table 3 Univariate and multivariate analysis of clinicopathologic variables in relation to overall survival and progression free survival in patients with rectal neuroendocrine neoplasms

	Univariate analysis1		Multivariate analysis1		Univariate analysis2		Multivariate analysis2
	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Sex (male)	1.148 (0.588-2.243)	0.686			1.168 (0.648-2.106)	0.605
Age (> 60)	2.194 (1.115-4.317)	0.023			2.875 (1.505-5.495)	< 0.001
PLR (> 128.00)	1.592 (0.818-3.100)	0.171			1.313 (0.668-2.577)	0.402
NLR (> 1.45)	1.629 (0.740-3.585)	0.226			2.322 (1.106-4.874)	0.007
PNI (> 46.57)	0.144 (0.071-0.295)	0.023	0.233 (0.109-0.499)	< 0.001	0.130 (0.043-0.392)	< 0.001	0.365 (0.135-0.583)	0.010
Size (cm)
≤ 1	-	Ref.	-	Ref.	-	Ref.
1-2	6.190 (2.591-14.790)	< 0.001	1.706 (0.538-5.413)	0.364	4.960 (1.956-12.580)	0.001
> 2	13.439 (5.563-32.468)	< 0.001	3.349 (1.314-8.533)	0.011	10.240 (5.200-25.200)	< 0.001
Pathological type
NET	-	Ref.			-	Ref.
NEC	31.177 (14.961-64.968)	< 0.001			15.121 (5.590-59.102)	< 0.001
MANEC	27.899 (6.399-121.627)	< 0.001			26.252 (6.203-85.32)	< 0.001
Pathological grade
G1	-	Ref.	-	Ref.	-	Ref.	-	Ref.
G2	6.380 (2.582-15.768)	0.001	4.211 (1.603-11.059)	0.004	8.680 (2.830-20.602)	< 0.001	2.937 (1.011-8.535)	0.048
G3	48.175 (21.495-107.969)	< 0.001	30.681 (10.821-86.988)	< 0.001	25.362 (6.362-62.325)	< 0.001	7.126 (2.685-18.913)	< 0.001
T stage
T1	-	Ref.			-	Ref.	-	Ref.
T2	3.234 (1.169-8.945)	0.024			13.370 (3.794-47.086)	< 0.001	2.136 (1.236-5.362)	0.025
T3	17.473 (7.846-38.915)	< 0.001			12.630 (2.635-18.354)	< 0.001	6.653 (2.368-15.362)	0.001
T4	23.081 (8.328-63.964)	< 0.001			26.368 (5.364-53.258)	< 0.001	8.365 (3.325-13.325)	< 0.001
Lymph node metastasis (yes)	11.387 (5.786-22.409)	< 0.001			12.440 (4.172-37.112)	< 0.001
TNM stage
I	-	Ref.			-	Ref.
II	3.280 (1.188-9.056)	0.022			6.839 (1.692-27.650)	0.006
III	14.524 (7.080-29.797)	< 0.001			17.792 (5.982-52.932)	< 0.001
Lymph vascular invasion (yes)	5.753 (2.013-16.447)	0.001			5.899 (1.213-28.703)	< 0.001
CgA (positive)	1.992 (1.012-3.919)	0.046			1.188 (0.608-2.322)	0.512
Syn (positive)	1.161 (0.541-2.492)	0.702			0.960 (0.483-1.908)	0.919
Adjuvant therapy (yes)	10.775 (5.161-22.499)	< 0.001			13.110 (3.737-45.962)	< 0.001

¹Overall survival.

²Progress free survival.

PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; PNI: Prognostic nutritional index; NET: Neuroendocrine tumor; NEC: Neuroendocrine carcinoma; MANEC: Mixed adenoneuroendocrine carcinoma; CgA: Chromogranin A; Syn: Synaptophysin; HR: Hazard ratio; CI: confidence interval.